tiprankstipranks
Vigil Neuroscience Advances IGNITE Trial, Eyes Accelerated Approval
Company Announcements

Vigil Neuroscience Advances IGNITE Trial, Eyes Accelerated Approval

Don't Miss our Black Friday Offers:

Vigil Neuroscience Inc (VIGL) has provided an announcement.

Vigil Neuroscience, Inc. has announced an update on its IGNITE Phase 2 clinical trial, opting to preserve data for a comprehensive 12-month analysis, foregoing an interim analysis. This move is aligned with the company’s biomarker strategy and aims to expedite the potential accelerated approval pathway for its drug iluzanebart. Final results, covering all patient data at two dosage levels, are expected in the first half of 2025. However, the company cautions that factors like clinical trial delays could affect outcomes, as detailed in their SEC filings.

Find detailed analytics on VIGL stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskVigil Neuroscience Advances Key Clinical Programs
TheFlyVigil Neuroscience reports Q3 EPS (47c), consensus (54c)
TheFlyVigil Neuroscience story ‘gaining momentum,’ says Jefferies
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App